Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 331

1.

Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events.

Hoefsmit EP, Rozeman EA, Haanen JBAG, Blank CU.

ESMO Open. 2019 Jul 21;4(4):e000472. doi: 10.1136/esmoopen-2018-000472. eCollection 2019. Review.

PMID:
31423333
2.

A conserved Mcm4 motif is required for Mcm2-7 double-hexamer formation and origin DNA unwinding.

Champasa K, Blank C, Friedman LJ, Gelles J, Bell SP.

Elife. 2019 Aug 6;8. pii: e45538. doi: 10.7554/eLife.45538.

3.

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.

Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil CM, Lotem M, Larkin JMG, Lorigan P, Neyns B, Blank CU, Petrella TM, Hamid O, Su SC, Krepler C, Ibrahim N, Long GV.

Lancet Oncol. 2019 Jul 22. pii: S1470-2045(19)30388-2. doi: 10.1016/S1470-2045(19)30388-2. [Epub ahead of print]

PMID:
31345627
4.

Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry.

Jochems A, van der Kooij MK, Fiocco M, Schouwenburg MG, Aarts MJ, van Akkooi AC, van den Berkmortel FWPJ, Blank CU, van den Eertwegh AJM, Franken MG, de Groot JB, Haanen JBAG, Hospers GAP, Koornstra RH, Kruit WHJ, Louwman M, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, van Zeijl MCT, van der Hoeven KJM, Kapiteijn E.

Cancers (Basel). 2019 Jul 18;11(7). pii: E1007. doi: 10.3390/cancers11071007.

5.

Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold.

Vredevoogd DW, Kuilman T, Ligtenberg MA, Boshuizen J, Stecker KE, de Bruijn B, Krijgsman O, Huang X, Kenski JCN, Lacroix R, Mezzadra R, Gomez-Eerland R, Yildiz M, Dagidir I, Apriamashvili G, Zandhuis N, van der Noort V, Visser NL, Blank CU, Altelaar M, Schumacher TN, Peeper DS.

Cell. 2019 Jul 25;178(3):585-599.e15. doi: 10.1016/j.cell.2019.06.014. Epub 2019 Jul 11.

PMID:
31303383
6.

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA; International Neoadjuvant Melanoma Consortium members, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV.

Lancet Oncol. 2019 Jul;20(7):e378-e389. doi: 10.1016/S1470-2045(19)30332-8. Review.

PMID:
31267972
7.

Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).

De Bruijn RE, Mulders P, Jewett MA, Wagstaff J, Van Thienen JV, Blank CU, Van Velthoven R, Wood L, van Melick HE, Aarts MJ, Lattouf JB, Powles T, De Jong IJ, Rottey S, Tombal B, Marreaud S, Collette S, Collette L, Haanen JB, Bex A.

Eur Urol. 2019 Jun 18. pii: S0302-2838(19)30455-5. doi: 10.1016/j.eururo.2019.06.006. [Epub ahead of print]

PMID:
31227307
8.

Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.

Kreft S, Gesierich A, Eigentler T, Franklin C, Valpione S, Ugurel S, Utikal J, Haferkamp S, Blank C, Larkin J, Garbe C, Schadendorf D, Lorigan P, Schilling B.

Eur J Cancer. 2019 Jul;116:207-215. doi: 10.1016/j.ejca.2019.05.015. Epub 2019 Jun 15.

PMID:
31212163
9.

Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong S, Wiersma TG, Russell NS, Lalezari F, Schouten PC, Bakker NAM, Ketelaars SLC, Peters D, Lange CAH, van Werkhoven E, van Tinteren H, Mandjes IAM, Kemper I, Onderwater S, Chalabi M, Wilgenhof S, Haanen JBAG, Salgado R, de Visser KE, Sonke GS, Wessels LFA, Linn SC, Schumacher TN, Blank CU, Kok M.

Nat Med. 2019 Jul;25(7):1175. doi: 10.1038/s41591-019-0520-5.

PMID:
31209337
10.

Compliance with needle-use declarations at two Olympic Winter Games: Sochi (2014) and PyeongChang (2018).

Schobersberger W, Blank C, Budgett R, Pipe A, Stuart MC.

Br J Sports Med. 2019 Jun 15. pii: bjsports-2018-100342. doi: 10.1136/bjsports-2018-100342. [Epub ahead of print]

PMID:
31203198
11.

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJ, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Lupinacci R, Krepler C, Ibrahim N, Kicinski M, Marreaud S, van Akkooi AC, Suciu S, Robert C.

Eur J Cancer. 2019 Jul;116:148-157. doi: 10.1016/j.ejca.2019.05.020. Epub 2019 Jun 11.

PMID:
31200321
12.

Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors.

Rogiers A, Boekhout A, Schwarze JK, Awada G, Blank CU, Neyns B.

J Oncol. 2019 Apr 28;2019:5269062. doi: 10.1155/2019/5269062. eCollection 2019. Review.

13.

Combining checkpoint inhibition and targeted therapy in melanoma.

Rozeman EA, Blank CU.

Nat Med. 2019 Jun;25(6):879-882. doi: 10.1038/s41591-019-0482-7. No abstract available.

PMID:
31171877
14.

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.

Rozeman EA, Menzies AM, van Akkooi ACJ, Adhikari C, Bierman C, van de Wiel BA, Scolyer RA, Krijgsman O, Sikorska K, Eriksson H, Broeks A, van Thienen JV, Guminski AD, Acosta AT, Ter Meulen S, Koenen AM, Bosch LJW, Shannon K, Pronk LM, Gonzalez M, Ch'ng S, Grijpink-Ongering LG, Stretch J, Heijmink S, van Tinteren H, Haanen JBAG, Nieweg OE, Klop WMC, Zuur CL, Saw RPM, van Houdt WJ, Peeper DS, Spillane AJ, Hansson J, Schumacher TN, Long GV, Blank CU.

Lancet Oncol. 2019 Jul;20(7):948-960. doi: 10.1016/S1470-2045(19)30151-2. Epub 2019 May 31.

PMID:
31160251
15.

Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program.

Bisschop C, Wind TT, Blank CU, Koornstra RHT, Kapiteijn E, Van den Eertwegh AJM, De Groot JWB, Jalving M, Hospers GAP.

J Immunother. 2019 Jul/Aug;42(6):208-214. doi: 10.1097/CJI.0000000000000271.

PMID:
31145233
16.

Does Physical Activity during Alpine Vacations increase Tourists' Well-Being?

Schlemmer P, Blank C, Schnitzer M.

Int J Environ Res Public Health. 2019 May 15;16(10). pii: E1707. doi: 10.3390/ijerph16101707.

17.

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong S, Wiersma TG, Russell NS, Lalezari F, Schouten PC, Bakker NAM, Ketelaars SLC, Peters D, Lange CAH, van Werkhoven E, van Tinteren H, Mandjes IAM, Kemper I, Onderwater S, Chalabi M, Wilgenhof S, Haanen JBAG, Salgado R, de Visser KE, Sonke GS, Wessels LFA, Linn SC, Schumacher TN, Blank CU, Kok M.

Nat Med. 2019 Jun;25(6):920-928. doi: 10.1038/s41591-019-0432-4. Epub 2019 May 13. Erratum in: Nat Med. 2019 Jun 17;:.

PMID:
31086347
18.

Feasibility of Ski Mountaineering for Patients Following a Total Knee Arthroplasty: A Descriptive Field Study.

Haslinger S, Huber D, Morawetz D, Blank C, Prossegger J, Dünnwald T, Koller A, Fink C, Hartl A, Schobersberger W.

Int J Environ Res Public Health. 2019 May 6;16(9). pii: E1582. doi: 10.3390/ijerph16091582.

19.

Colonization, Baker's law, and the evolution of gynodioecy in Hawaii: implications from a study of Lycium carolinianum.

Miller JS, Blank CM, Levin RA.

Am J Bot. 2019 May;106(5):733-743. doi: 10.1002/ajb2.1279. Epub 2019 May 1.

PMID:
31042317
20.

The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment.

O'Donnell JS, Hoefsmit EP, Smyth MJ, Blank CU, Teng MWL.

Clin Cancer Res. 2019 Apr 30. doi: 10.1158/1078-0432.CCR-18-2641. [Epub ahead of print] Review.

PMID:
31040150
21.

A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX).

Bex A, van Thienen JV, Schrier M, Graafland N, Kuusk T, Hendricksen K, Lagerveld B, Zondervan P, van Moorselaar JA, Blank C, Wilgenhof S, Haanen J.

Future Oncol. 2019 Jul;15(19):2203-2209. doi: 10.2217/fon-2019-0111. Epub 2019 Apr 26. Erratum in: Future Oncol. 2019 Aug;15(22):2667.

PMID:
31023100
22.

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma.

van Herpen CML, Agarwala SS, Hauschild A, Berking C, Beck JT, Schadendorf D, Jansen R, Queirolo P, Ascierto PA, Blank CU, Heinrich MC, Pal RR, Derti A, Antona V, Nauwelaerts H, Zubel A, Dummer R.

Oncotarget. 2019 Mar 5;10(19):1850-1859. doi: 10.18632/oncotarget.26753. eCollection 2019 Mar 5.

23.

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.

Jansen YJL, Rozeman EA, Mason R, Goldinger SM, Geukes Foppen MH, Hoejbergs L, Schmidt H, van Thienen JV, Haanen JBAG, Tiainen L, Svane IM, Mäkelä S, Seremet T, Arance A, Dummer R, Bastholt L, Nyakas M, Straume O, Menzies AM, Long GV, Atkinson V, Blank CU, Neyns B.

Ann Oncol. 2019 Mar 28. pii: mdz110. doi: 10.1093/annonc/mdz110. [Epub ahead of print]

PMID:
30923820
24.

Sex-Related Differences After a Single Bout of Maximal Eccentric Exercise in Response to Acute Effects: A Systematic Review and Meta-analysis.

Morawetz D, Blank C, Koller A, Arvandi M, Siebert U, Schobersberger W.

J Strength Cond Res. 2019 Mar 15. doi: 10.1519/JSC.0000000000002867. [Epub ahead of print]

PMID:
30908366
25.

Predicting Response to Cancer Immunotherapy using Non-invasive Radiomic Biomarkers.

Trebeschi S, Drago SG, Birkbak NJ, Kurilova I, Cǎlin AM, Pizzi AD, Lalezari F, Lambregts DMJ, Rohaan M, Parmar C, Hartemink KJ, Swanton C, Haanen JBAG, Blank CU, Smit EF, Beets-Tan RGH, Aerts HJWL.

Ann Oncol. 2019 Mar 21. pii: mdz108. doi: 10.1093/annonc/mdz108. [Epub ahead of print]

26.

Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma.

Schermers B, Franke V, Rozeman EA, van de Wiel BA, Bruining A, Wouters MW, van Houdt WJ, Ten Haken B, Muller SH, Bierman C, Ruers TJM, Blank CU, van Akkooi ACJ.

Br J Surg. 2019 Apr;106(5):519-522. doi: 10.1002/bjs.11168. Epub 2019 Mar 18.

27.

Dedicated Ultrasound Speckle Tracking for Quantitative Analysis of Uterine Motion Outside Pregnancy.

Sammali F, Kuijsters NPM, Huang Y, Blank C, Rabotti C, Schoot BC, Mischi M.

IEEE Trans Ultrason Ferroelectr Freq Control. 2019 Mar;66(3):581-590. doi: 10.1109/TUFFC.2018.2867098.

PMID:
30872213
28.

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis.

Schilling B, Martens A, Geukes Foppen MH, Gebhardt C, Hassel JC, Rozeman EA, Gesierich A, Gutzmer R, Kähler KC, Livingstone E, Diamantopoulos PT, Gogas H, Madonna G, Ascierto PA, Goldinger SM, Mangana J, Garbe C, Schadendorf D, Blank C, Weide B.

Cancer Immunol Immunother. 2019 May;68(5):765-772. doi: 10.1007/s00262-019-02311-1. Epub 2019 Feb 26.

PMID:
30806748
29.

A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanoma.

Wind TT, Jalving M, de Haan JJ, de Vries EGE, van Vugt MATM, Reijngoud DJ, van Rijn RS, Haanen JBAG, Blank CU, Hospers GAP, Fehrmann RSN.

Oncoimmunology. 2019 Jan 3;8(3):1558664. doi: 10.1080/2162402X.2018.1558664. eCollection 2019.

30.

Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy.

Liu J, Rozeman EA, O'Donnell JS, Allen S, Fanchi L, Smyth MJ, Blank CU, Teng MWL.

Oncoimmunology. 2018 Nov 22;8(2):e1546068. doi: 10.1080/2162402X.2018.1546068. eCollection 2019.

PMID:
30713806
31.

Prediction of implantation after blastocyst transfer in in vitro fertilization: a machine-learning perspective.

Blank C, Wildeboer RR, DeCroo I, Tilleman K, Weyers B, de Sutter P, Mischi M, Schoot BC.

Fertil Steril. 2019 Feb;111(2):318-326. doi: 10.1016/j.fertnstert.2018.10.030. Epub 2019 Jan 2.

PMID:
30611557
32.

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma.

Li H, van der Leun AM, Yofe I, Lubling Y, Gelbard-Solodkin D, van Akkooi ACJ, van den Braber M, Rozeman EA, Haanen JBAG, Blank CU, Horlings HM, David E, Baran Y, Bercovich A, Lifshitz A, Schumacher TN, Tanay A, Amit I.

Cell. 2019 Feb 7;176(4):775-789.e18. doi: 10.1016/j.cell.2018.11.043. Epub 2018 Dec 27.

PMID:
30595452
33.

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system.

Larkin J, Brown MP, Arance AM, Hauschild A, Queirolo P, Vecchio MD, Ascierto PA, Krajsová I, Schachter J, Neyns B, Garbe C, Sileni VC, Mandalà M, Gogas H, Espinosa E, Hospers G, Lorigan P, Nyakas M, Guminski A, Liszkay G, Rutkowski P, Miller W Jr, Donica M, Makrutzki M, Blank C.

Eur J Cancer. 2019 Jan;107:175-185. doi: 10.1016/j.ejca.2018.11.018. Epub 2018 Dec 20.

PMID:
30580112
34.

Survival After Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy.

Batzner A, Pfeiffer B, Neugebauer A, Aicha D, Blank C, Seggewiss H.

J Am Coll Cardiol. 2018 Dec 18;72(24):3087-3094. doi: 10.1016/j.jacc.2018.09.064.

PMID:
30545446
35.

Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.

Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU, van Velthoven R, Del Pilar Laguna M, Wood L, van Melick HHE, Aarts MJ, Lattouf JB, Powles T, de Jong Md PhD IJ, Rottey S, Tombal B, Marreaud S, Collette S, Collette L, Haanen J.

JAMA Oncol. 2019 Feb 1;5(2):164-170. doi: 10.1001/jamaoncol.2018.5543. Erratum in: JAMA Oncol. 2019 Feb 1;5(2):271.

PMID:
30543350
36.

Effects of Recreational Ski Mountaineering on Cumulative Muscle Fatigue - A Longitudinal Trial.

Haslinger S, Blank C, Morawetz D, Koller A, Dünnwald T, Berger S, Schlickum N, Schobersberger W.

Front Physiol. 2018 Nov 27;9:1687. doi: 10.3389/fphys.2018.01687. eCollection 2018.

37.

Remission of psoriasis during treatment with sorafenib.

van Kester MS, Luelmo SAC, Vermeer MH, Blank C, van Doorn R.

JAAD Case Rep. 2018 Nov 14;4(10):1065-1067. doi: 10.1016/j.jdcr.2018.09.009. eCollection 2018 Nov. No abstract available.

38.

Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.

Brummer C, Faerber S, Bruss C, Blank C, Lacroix R, Haferkamp S, Herr W, Kreutz M, Renner K.

Cancer Lett. 2019 Feb 1;442:453-463. doi: 10.1016/j.canlet.2018.11.018. Epub 2018 Nov 24.

PMID:
30481565
39.

Arts-Based Research Approaches to Studying Mechanisms of Change in the Creative Arts Therapies.

Gerber N, Bryl K, Potvin N, Blank CA.

Front Psychol. 2018 Nov 1;9:2076. doi: 10.3389/fpsyg.2018.02076. eCollection 2018.

40.

External validation of a prediction model to select the best day-three embryo for transfer in in vitro fertilization or intracytoplasmatic sperm injection procedures.

Blank C, Duijf IT, Slappendel E, Mischi M, Houterman S, Maas JWM, de Sutter P, Schoot BC.

Fertil Steril. 2018 Oct;110(5):917-924. doi: 10.1016/j.fertnstert.2018.06.004.

PMID:
30316438
41.

Influence of dietary zinc concentration and supplemental zinc source on nutrient digestibility, zinc absorption, and retention in sheep.

VanValin KR, Genther-Schroeder ON, Carmichael RN, Blank CP, Deters EL, Hartman SJ, Niedermayer EK, Laudert SB, Hansen SL.

J Anim Sci. 2018 Dec 3;96(12):5336-5344. doi: 10.1093/jas/sky384.

PMID:
30299509
42.

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.

Blank CU, Rozeman EA, Fanchi LF, Sikorska K, van de Wiel B, Kvistborg P, Krijgsman O, van den Braber M, Philips D, Broeks A, van Thienen JV, Mallo HA, Adriaansz S, Ter Meulen S, Pronk LM, Grijpink-Ongering LG, Bruining A, Gittelman RM, Warren S, van Tinteren H, Peeper DS, Haanen JBAG, van Akkooi ACJ, Schumacher TN.

Nat Med. 2018 Nov;24(11):1655-1661. doi: 10.1038/s41591-018-0198-0. Epub 2018 Oct 8.

PMID:
30297911
43.

The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.

van Dijk N, Funt SA, Blank CU, Powles T, Rosenberg JE, van der Heijden MS.

Eur Urol. 2019 Mar;75(3):435-444. doi: 10.1016/j.eururo.2018.09.022. Epub 2018 Sep 28. Review.

PMID:
30274701
44.

Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.

Carlino MS, Long GV, Schadendorf D, Robert C, Ribas A, Richtig E, Nyakas M, Caglevic C, Tarhini A, Blank C, Hoeller C, Bar-Sela G, Barrow C, Wolter P, Zhou H, Emancipator K, Jensen EH, Ebbinghaus S, Ibrahim N, Daud A.

Eur J Cancer. 2018 Sep;101:236-243. doi: 10.1016/j.ejca.2018.06.034. Epub 2018 Aug 7.

45.

Targeting tumor-associated acidity in cancer immunotherapy.

Lacroix R, Rozeman EA, Kreutz M, Renner K, Blank CU.

Cancer Immunol Immunother. 2018 Sep;67(9):1331-1348. doi: 10.1007/s00262-018-2195-z. Epub 2018 Jul 5. Review.

PMID:
29974196
46.

Community-Driven Data Analysis Training for Biology.

Batut B, Hiltemann S, Bagnacani A, Baker D, Bhardwaj V, Blank C, Bretaudeau A, Brillet-Guéguen L, Čech M, Chilton J, Clements D, Doppelt-Azeroual O, Erxleben A, Freeberg MA, Gladman S, Hoogstrate Y, Hotz HR, Houwaart T, Jagtap P, Larivière D, Le Corguillé G, Manke T, Mareuil F, Ramírez F, Ryan D, Sigloch FC, Soranzo N, Wolff J, Videm P, Wolfien M, Wubuli A, Yusuf D; Galaxy Training Network, Taylor J, Backofen R, Nekrutenko A, Grüning B.

Cell Syst. 2018 Jun 27;6(6):752-758.e1. doi: 10.1016/j.cels.2018.05.012.

47.

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.

Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, van de Wiel BA, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, van Akkooi ACJ, van Houdt WJ, Mitchell TC, Menzies AM, Long GV, Wargo JA, Davies MA, Prieto VG, Taube JM, Scolyer RA.

Ann Oncol. 2018 Aug 1;29(8):1861-1868. doi: 10.1093/annonc/mdy226.

48.

Primum non nocere: earlier cessation of glucose monitoring is possible.

Blank C, van Dillen J, Hogeveen M.

Eur J Pediatr. 2018 Aug;177(8):1239-1245. doi: 10.1007/s00431-018-3169-z. Epub 2018 May 30.

49.

The influence of supplemental zinc and ractopamine hydrochloride on trace mineral and nitrogen retention of beef steers.

Carmichael RN, Genther-Schroeder ON, Blank CP, Deters EL, Hartman SJ, Niedermayer EK, Hansen SL.

J Anim Sci. 2018 Jun 29;96(7):2939-2948. doi: 10.1093/jas/sky177.

50.

The effects of 8 weeks of two different training methods on on-sight lead climbing performance.

Philippe M, Filzwieser I, Leichtfried V, Blank C, Haslinger S, Fleckenstein J, Schobersberger W.

J Sports Med Phys Fitness. 2019 Apr;59(4):561-568. doi: 10.23736/S0022-4707.18.08399-8. Epub 2018 May 2.

PMID:
29722250

Supplemental Content

Support Center